506 related articles for article (PubMed ID: 30154038)
1. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.
Issa I; Skov J; Falhammar H; Calissendorff J; Lindh JD; Mannheimer B
Eur J Clin Pharmacol; 2023 Jan; 79(1):71-77. PubMed ID: 36380227
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
4. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
6. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Escoffier J; Arnaud B; Kaba M; Hograindleur JP; Le Blévec E; Martinez G; Stévant I; Ray PF; Arnoult C; Nef S
Andrology; 2020 Nov; 8(6):1795-1804. PubMed ID: 32609951
[TBL] [Abstract][Full Text] [Related]
7. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Zeng C; Neogi T; Chan AT; Wei J; Misra D; Lu N; Choi HK; Lei G; Zhang Y
Osteoarthritis Cartilage; 2022 Apr; 30(4):559-569. PubMed ID: 35031493
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
11. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.
Sun Y; Zhang A; Zuo M; Chen J; Zhu L
J Gastroenterol Hepatol; 2024 Feb; 39(2):289-296. PubMed ID: 37961012
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotics and severe hyponatremia: A Swedish population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Feb; 60():71-77. PubMed ID: 30514607
[TBL] [Abstract][Full Text] [Related]
13. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous reactions to proton pump inhibitors: a case-control study.
Chularojanamontri L; Jiamton S; Manapajon A; Suvanasuthi S; Kulthanan K; Dhana N; Jongjarearnprasert K
J Drugs Dermatol; 2012 Oct; 11(10):e43-7. PubMed ID: 23134998
[TBL] [Abstract][Full Text] [Related]
15. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
[TBL] [Abstract][Full Text] [Related]
19. Association Between Proton Pump Inhibitors and Microscopic Colitis.
Law EH; Badowski M; Hung YT; Weems K; Sanchez A; Lee TA
Ann Pharmacother; 2017 Mar; 51(3):253-263. PubMed ID: 27733667
[TBL] [Abstract][Full Text] [Related]
20. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
